Chardan Capital Maintains Buy on Avidity Biosciences, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Avidity Biosciences (NASDAQ:RNA) and raises the price target from $45 to $60.
August 09, 2024 | 9:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital analyst Keay Nakae maintains a Buy rating on Avidity Biosciences and raises the price target from $45 to $60.
The raised price target from $45 to $60 by Chardan Capital is a positive signal for investors, indicating increased confidence in Avidity Biosciences' future performance. This is likely to result in a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100